Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Collagens in primary frozen shoulder: expression of collagen mRNA isoforms in the different phases of the disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: To compare treatment retention and response to secukinumab vs adalimumab, including the other four TNF inhibitors (TNFi) as comparators, in PsA.

METHODS: All patients with PsA starting secukinumab or a TNFi in 2015-2018 were identified in the biologic registers of the Nordic countries. Data on comorbidities were linked from national registers. One-year treatment retention and hazard ratios (HRs) for treatment discontinuation were calculated. The proportion achieving a 6 month 28-joint Disease Activity Index for Psoriatic Arthritis (DAPSA28) remission was determined together with odds ratios (ORs) for remission (logistic regression). Both HRs and ORs were calculated with adalimumab as the reference and adjusted for baseline characteristics and concurrent comorbidities. All analyses were stratified by the line of biologic treatment (first, second, third+).

RESULTS: We identified 6143 patients contributing 8307 treatment courses (secukinumab, 1227; adalimumab, 1367). Secukinumab was rarely used as the first biologic, otherwise baseline characteristics were similar. No clinically significant differences in treatment retention or response rates were observed for secukinumab vs adalimumab. The adjusted HRs for discontinuation per the first, second and third line of treatment were 0.98 (95% CI 0.68, 1.41), 0.94 (0.70, 1.26) and 1.07 (0.84, 1.36), respectively. The ORs for DAPSA28 remission in the first, second and third line of treatment were 0.62 (95% CI 0.30, 1.28), 0.85 (0.41, 1.78) and 0.74 (0.36, 1.51), respectively. In the subset of patients previously failing a TNFi due to ineffectiveness, the results were similar.

CONCLUSION: No significant differences in treatment retention or response were observed between secukinumab and adalimumab, regardless of the line of treatment. This suggests that even in patients who have failed a TNFi, choosing either another TNFi or secukinumab may be equally effective.

Original languageEnglish
JournalRheumatology (Oxford, England)
Volume60
Issue number8
Pages (from-to)3635-3645
Number of pages11
ISSN1462-0324
DOIs
Publication statusPublished - 2 Aug 2021

    Research areas

  • Adult, Aged, Antibodies, Monoclonal, Humanized/therapeutic use, Arthritis, Psoriatic/drug therapy, Female, Humans, Male, Medication Adherence/statistics & numerical data, Middle Aged, Treatment Outcome, Tumor Necrosis Factor Inhibitors/therapeutic use, treatment, secukinumab, adalimumab, response, psoriatic arthritis, retention

ID: 67549697